GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
ATHERSYS INC (ATHX) [hlAlert]

Rating:
Buy ATHX
down 22.44 %

ATHERSYS INC (ATHX) rated Buy with price target $6 by Maxim Group

Posted on: Friday,  Oct 5, 2012  8:25 AM ET by Maxim Group

Maxim Group rated Buy ATHERSYS INC (NASDAQ: ATHX) on 10/05/2012. Previously Maxim Group rated Buy ATHERSYS INC (NASDAQ: ATHX) on 05/31/2012.,
when the stock price was $1.47. Since then, ATHERSYS INC has lost 22.45% as of 01/26/2016's recent price of $1.14.
If you would have followed the previous Maxim Group's recommendation on ATHX, you would have lost 22.44% of your investment in 1335 days.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company?s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/28/2014 12:00 AM Buy
None
1.33 7.00
as of 12/31/2012
1 Week down  -4.50 %
1 Month   
3 Months down  -23.74 %
1 YTD down  -25.87 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/19/2013 3:25 PM Buy
None
2.11 10.00
10/5/2012 8:25 AM Buy
None
1.43 6.00
5/31/2012 10:25 AM Buy
None
1.47 3.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy